Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015951 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
A Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
NCT00015951: Completed Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by University of Maryland, Baltimore.
NCT00015951 is a Phase 2 study of Leukemia and Myelodysplastic Syndromes that has completed, run by University of Maryland, Baltimore. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015951, a Phase 2 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
- DRUG cytarabine
- DRUG mitoxantrone hydrochloride
Study Locations (3)
Maryland
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland - Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00015951 record still lists
NCT00015951 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which bevacizumab is the first listed.
NCT00015951 reports a single indexed study location in Maryland, Georgia.
Frequently Asked Questions
What is clinical trial NCT00015951 about?
NCT00015951 is a clinical study titled "Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers". RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase I...
What is the current status of trial NCT00015951?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2004-03.
What conditions does trial NCT00015951 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT00015951?
The interventions under investigation include: bevacizumab (BIOLOGICAL), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00015951?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015951 being conducted?
This trial has 3 study locations across Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia